

# **Chapter 14**

**Digoxin Synthesis and Endosymbiotic Human  
Genomic Archaeal Sequences - The Steroidelle**

## Introduction

Endomyocardial fibrosis (EMF) along with the root wilt disease of coconut is endemic to Kerala with its radioactive actinide beach sands. Actinides like rutile, endogenous digoxin as well as organisms like phytoplasmas and viroids have been implicated in the etiology of these diseases.<sup>1-4</sup> Endogenous digoxin has been related to the pathogenesis of schizophrenia, malignancy, metabolic syndrome X, autoimmune disease and neuronal degeneration.<sup>4</sup> The possibility of endogenous digoxin synthesis by actinide based primitive organism like archaea with a mevalonate pathway and cholesterol catabolism was considered.<sup>5-8</sup> An actinide dependent shadow biosphere of archaea in the above mentioned disease states is described.<sup>7,9</sup>

Global warming induces endosymbiotic archaeal and RNA viroidal growth. The porphyrins form a template for the formation of RNA viroids, DNA viroids, prions, isoprenoids and polysaccharides. They can symbiose together to form primitive archaea. The archaea can further induce HIF alpha, aldose reductase and fructolysis resulting in further porphyrinogenesis and archaeal self replication. The primitive archaeal DNA is integrated along with RNA viroids which are converted to their corresponding DNA by the action of redox stress induced HERV reverse transcriptase into the human genome by the redox stress induced HERV integrase. The archaeal DNA sequences that are integrated into the human genome forms endogenous archaeal human genomic sequences akin to HERV sequences and can function as jumping genes regulating genomic DNA flexibility. The integrated endogenous genomic archaeal sequences can get expressed in the presence of redox stress forming endosymbiotic archaeal particles which can function as a new organelle called the archaeons. The archaeon can express the fructolytic pathway constituting an organelle called the fructosome, cholesterol catabolic pathway and digoxin synthetic forming an

organelle called the steroidelle, the shikimic acid pathway forming an organelle called the neurotransminoid, antioxidant vitamin E and vitamin C synthetic organelle called the vitaminocyte as well as the glycosaminoglycan synthetic organelle called glycosaminoglycoid. The archaea can secrete capsulated RNA viroidal particles which can function as blocking RNAs modulating cell metabolism and such archaeon organelle are called viroidelle. The archaea suppresses pyruvate dehydrogenase and promotes fructolysis resulting in accumulation of pyruvate which enters the GABA shunt pathway producing succinyl CoA and glycine, the substrates for porphyrin synthesis. Porphyrin forms a template for the formation of RNA viroids, DNA viroids, prions and isoprenoids which can symbiose together to form an archaea. Thus endosymbiotic archaea have an abiogenic replication. The archaeon concerned with GABA shunt pathway and porphyrinogenesis are called porphyrinoids. The archaeon colony forms a network with different areas showing differential specialization of function - fructosoids, steroidelle, vitaminocyte, viroidelle, neurotransminoid, porphyrinoids and glycosaminoglycoids. This forms a living organized structure within human cells and tissues regulating their function and reducing the human body to zombie working under the directions of the organized archaeal colony. The organized archaeal colony has abiogenetic replication and is eternal.

The increase in endogenous EDLF, a potent inhibitor of membrane  $\text{Na}^+\text{-K}^+$  ATPase, can decrease this enzyme activity. The results showed increased endogenous EDLF synthesis as evidenced by increased HMG CoA reductase activity, which functions as the rate limiting step of the isoprenoid pathway. Studies in our laboratory have demonstrated that EDLF is synthesized by the isoprenoid pathway. The endosymbiotic archaeal sequences in the human genome get expressed by redox stress and osmotic stress of global warming. This results in induction of HIF alpha which will upregulate fructolysis and

glycolysis. In the setting of redox stress all glucose gets converted to fructose by the induction of enzymes aldose reductase and sorbitol dehydrogenase. Aldose reductase converts glucose to sorbitol and sorbitol dehydrogenase converts sorbitol to fructose. Since fructose is preferentially phosphorylated by ketohexokinases the cell is depleted of ATP and glucose phosphorylation comes to a halt. Fructose becomes the dominant sugar that is metabolized by fructolysis in expressed archaeal particles in the cell functioning as organelle called fructosoids. The fructose is phosphorylated to fructose 1-phosphate which is acted upon by aldolase B which converts it into glyceraldehyde 3-phosphate and dihydroxy acetone phosphate. Glyceraldehyde 3-phosphate is converted to D 1,3-biphosphoglycerate which is then converted to 3-phosphoglycerate. The 3-phosphoglycerate is converted to 2-phosphoglycerate. 2-phosphoglycerate is converted to phosphoenol pyruvate by the enzyme enolase. Phosphoenol pyruvate is converted to pyruvate by the enzyme pyruvic kinase. The archaeon induces HIF alpha which upregulates fructolysis and glycolysis but inhibits pyruvate dehydrogenase. The forward metabolism of pyruvate is stopped. The dephosphorylation of phosphoenol pyruvate is inhibited in the setting of pyruvic kinase inhibition. Phosphoenol pyruvate enters the shikimic acid pathway where it is converted to chorismate. The shikimic acid is synthesized by a pathway starting from glyceraldehyde 3-phosphate. Glyceraldehyde 3-phosphate combines with the pentose phosphate pathway metabolite sedoheptulose 7-phosphate which is converted to erythrose 4-phosphate. The pentose phosphate pathway is upregulated in the presence of the suppression of glycolytic pathway. Erythrose 4-phosphate combines with phosphoenol pyruvate to generate shikimic acid. Shikimic acid combines with another molecule of phosphoenol pyruvate to generate chorismate. The chorismate is converted to prephenic acid and then to parahydroxy phenyl pyruvic acid. Parahydroxy phenyl pyruvic acid is converted to tyrosine and

tryptophan as well as neuroactive alkaloids. The shikimic acid pathway is structured in expressed archaeaon organelle called the neurotransminoid. The fructolytic intermediates glyceraldehyde 3-phosphate and pyruvate are the starting points of the DXP pathway of cholesterol synthesis. Glyceraldehyde 3-phosphate combines with pyruvate to form 1-Deoxy D-xylulose phosphate (DOXP) which is then converted to 2-C methyl erythritol phosphate. 2-C methyl erythritol phosphate can be synthesized from erythrose 4-phosphate a metabolite of the shikimic acid pathway. DXP combines with MEP to form isopentenyl pyrophosphate which is converted to cholesterol. Cholesterol is catabolized by archaeal cholesterol oxidases to generate digoxin. The digoxin sugars digitoxose and rhamnose are synthesized by the upregulated pentose phosphate pathway. Glycolytic suppression leads to upregulation of the pentose phosphate pathway. The expressed archaeaon organelle concerned with cholesterol catabolism and digoxin synthesis is called the steroidelle. The suppression of glycolysis and stimulation of fructolysis results in upregulation of the hexosamine pathway. Fructose is converted to fructose 6-phosphate by ketohexokinases. The fructose 6-phosphate is converted to glucosamine 6-phosphate by the action of glutamine fructose 6-phosphate amidotransferase (GFAT). Glucosamine 6-phosphate is converted to UDP N-acetyl glucosamine which is then converted to N-acetyl glucosamine and various amino sugars. UDP glucose is converted to UDP D-glucuronic acid. UDP D-glucuronic acid is converted to glucuronic acid. This forms the uronic acid synthetic pathway. Uronic acids and hexosamines form repeating units of glycosaminoglycans. In the setting of glycolytic suppression and fructolytic metabolism fructolysis leads to increase synthesis of hexosamines and GAG synthesis. The GAG synthesizing archaeaon particles are called the glycosaminoglycoids. The expressed archaeaon particles are capable of synthesizing antioxidant vitamin C and E. The UDP D-glucose is converted to UDP D-glucuronic acid. UDP

D-glucuronic acid is converted to D-glucuronic acid. D-glucuronic acid is converted to L-gulonate by enzyme aldoketo reductases. L-gulonate is converted to L-gulonolactone by lactonase. L-gulonolactone is converted to ascorbic acid by the action of archaeal L-gulo oxidase. The vitamin E is synthesized from shikimate which is converted to tyrosine and then to parahydroxy phenyl pyruvic acid. Parahydroxy phenyl pyruvic acid is converted to homogentisate. Homogentisate is converted to 2-methyl 6-phytyl benzoquinone which is converted to alpha tocopherol. 2-methyl 6-phytyl benzoquinone is converted to 2,3-methyl 6-phytyl benzoquinone and gamma tocopherol. Vitamin E can also be synthesized by the DXP pathway. Glyceraldehyde 3-phosphate and pyruvate combined to form 1-deoxy D-xylulose 5-phosphate which is converted to 3-isopentenyl pyrophosphate. 3-isopentenyl pyrophosphate and dimethyl allyl pyrophosphate combined to form 2-methyl 6-phytyl benzoquinone which is converted to tocopherols. The ubiquinone another important membrane antioxidant and part of the mitochondrial electron transport chain is synthesized by the shikimic acid pathway and DXP pathway. The isoprenoid moiety of ubiquinone is contributed from the DXP pathway and the rest of it by tyrosine catabolism. The tyrosine is generated by the shikimic acid pathway. The archaeon particles concerned with the synthesis of vitamin C, vitamin E and ubiquinone which are all antioxidants are called the vitaminocyte.

The endosymbiotic archaea gets integrated into the human genome by the action of HERV integrase. This forms human genomic endosymbiotic archaeal sequences which can regulate genomic function. The global warming results in osmotic stress and redox stress inducing the enzyme aldose reductase. This converts glucose to sorbitol is acted upon by sorbitol dehydrogenase generating fructose. Fructose is phosphorylated by fructokinase to generate fructose 1-phosphate which is acted upon by aldolase B to generate glyceraldehyde

3-phosphate and pyruvate. The glycolytic pathway is suppressed by fructosylation of glycolytic enzymes. Antibodies are developed against the fructosylated antigenic glycolytic enzymes. The archaeal synthesized digoxin induces intracellular magnesium depletion and glycolytic suppression. The pyruvate and glyceraldehyde 3-phosphate generated by fructolysis is acted upon by DOXP synthase converting it into 1-deoxy D xylulose 5-phosphate (DOXP). DOXP is acted upon by DOXP reductase which convert it into 2-C methyl erythritol 4-phosphate (MEP) which is then converted to isopentenyl pyrophosphate (IPP). IPP is converted to cholesterol which is used for digoxin synthesis. Thus endogenous digoxin synthesis occurs by the induction of the DOXP pathway. The endosymbiotic archaea are integrated into the human genome producing endogenous genomic archaeal sequences akin to HERV sequences. The global warming induced redox stress results in expression of endogenous genomic archaeal sequences and the DXP pathway enzymes contributing to cholesterol and digoxin synthesis. The fructose can enter the fructolytic pathway by the action of fructokinase and aldolase B. This generates fructose 1,6-diphosphate which can enter the pentose phosphate pathway scheme generating sugars like rhamnose and digitoxose.

In the pentose phosphate pathway glucose 6-phosphate is converted to 6-phosphogluconolactone which is then converted to 6-phosphogluconate. 6-phosphogluconate is converted to ribulose 5-phosphate which is then converted to xylulose 5-phosphate. Ribulose 5-phosphate can be converted to ribose 5-phosphate used for nucleic acid synthesis. The ribose 5-phosphate is acted upon by transketolase producing glyceraldehyde 3-phosphate and sedoheptulose 7-phosphate. Glyceraldehyde 3-phosphate and sedoheptulose 7-phosphate is acted upon by transaldolase producing erythrose 4-phosphate and fructose 6-phosphate. The digoxin glycoside sugars rhamnose and digitoxose are produced by the pentose phosphate pathway. Fructolysis results in upregulation of the pentose

phosphate pathway and the synthesis of pentose sugars.

Endogenous digoxin synthesis has been demonstrated in the human brain. Endogenous digoxin synthesis is induced by the expression of endogenous genomic archaeal sequences by redox stress and osmotic stress of global warming. This generates endosymbiotic archaea which can function as specialized organelle in the cell called the steroidelle which is involved in the digoxin synthesis. Digoxin plays a crucial role in neuro-immuno-endocrine integration.

## Materials and Methods

The following groups were included in the study: - endomyocardial fibrosis, Alzheimer's disease, multiple sclerosis, non-Hodgkin's lymphoma, metabolic syndrome X with cerebrovascular thrombosis and coronary artery disease, schizophrenia, autism, seizure disorder, Creutzfeldt Jakob's disease and acquired immunodeficiency syndrome. There were 10 patients in each group and each patient had an age and sex matched healthy control selected randomly from the general population. The blood samples were drawn in the fasting state before treatment was initiated. Plasma from fasting heparinised blood was used and the experimental protocol was as follows: (I) Plasma+phosphate buffered saline, (II) same as I+cholesterol substrate, (III) same as II+rutile 0.1 mg/ml, and (IV) same as II+ciprofloxacin and doxycycline each in a concentration of 1 mg/ml. Cholesterol substrate was prepared as described by Richmond.<sup>10</sup> Aliquots were withdrawn at zero time immediately after mixing and after incubation at 37 °C for 1 hour. The following estimations were carried out: - Cytochrome F420 and digoxin.<sup>11-13</sup> Cytochrome F420 was estimated fluorimetrically (excitation wavelength 420 nm and emission wavelength 520 nm). Informed consent of the subjects and the approval of the ethics committee were obtained for the study. The statistical analysis was done by ANOVA.

## Results

Plasma of control subjects showed increased levels of the above mentioned parameters with after incubation for 1 hour and addition of cholesterol substrate resulted in still further significant increase in these parameters. The plasma of patients showed similar results but the extent of increase was more. The addition of antibiotics to the control plasma caused a decrease in all the parameters while addition of rutil increased their levels. The addition of antibiotics to the patient's plasma caused a decrease in all the parameters while addition of rutil increased their levels but the extent of change was more in patient's sera as compared to controls. The results are expressed in tables 1-2 as percentage change in the parameters after 1 hour incubation as compared to the values at zero time.

**Table 1.** Effect of rutil and antibiotics on cytochrome F420.

Group	CYT F420 % (Increase with Rutil)		CYT F420 % (Decrease with Doxy+Cipro)	
	Mean	±SD	Mean	±SD
Normal	4.48	0.15	18.24	0.66
Schizo	23.24	2.01	58.72	7.08
Seizure	23.46	1.87	59.27	8.86
AD	23.12	2.00	56.90	6.94
MS	22.12	1.81	61.33	9.82
NHL	22.79	2.13	55.90	7.29
DM	22.59	1.86	57.05	8.45
AIDS	22.29	1.66	59.02	7.50
CJD	22.06	1.61	57.81	6.04
Autism	21.68	1.90	57.93	9.64
EMF	22.70	1.87	60.46	8.06
F value	306.749		130.054	
P value	< 0.001		< 0.001	

**Table 2.** *Effect of rutile and antibiotics on digoxin.*

Group	Digoxin (ng/ml) (Increase with Rutile)		Digoxin (ng/ml) (Decrease with Doxy+Cipro)	
	Mean	±SD	Mean	±SD
Normal	0.11	0.00	0.054	0.003
Schizo	0.55	0.06	0.219	0.043
Seizure	0.51	0.05	0.199	0.027
AD	0.55	0.03	0.192	0.040
MS	0.52	0.03	0.214	0.032
NHL	0.54	0.04	0.210	0.042
DM	0.47	0.04	0.202	0.025
AIDS	0.56	0.05	0.220	0.052
CJD	0.53	0.06	0.212	0.045
Autism	0.53	0.08	0.205	0.041
EMF	0.51	0.05	0.213	0.033
F value	135.116		71.706	
P value	< 0.001		< 0.001	

## Discussion

There was increase in cytochrome F420 indicating archaeal growth. The archaea can synthesize and use cholesterol as a carbon and energy source.<sup>6, 14</sup> The archaeal origin of the enzyme activities was indicated by antibiotic induced suppression. The study indicates the presence of actinide based archaea with an alternate actinide based enzymes or metalloenzymes in the system as indicated by rutile induced increase in enzyme activities.<sup>15, 16</sup> The archaeal beta hydroxyl steroid dehydrogenase activity indicating digoxin synthesis was increased.<sup>8</sup> The archaea can undergo magnetite and calcium carbonate mineralization and can exist as calcified nanofoms.<sup>17</sup>

Archaeal digoxin induced redox stress can produce histone deacetylase inhibition resulting in endogenous retroviral (HERV) reverse transcriptase and integrase expression. Digoxin can cut and paste the HERV RNA by modulating

RNA splicing generating RNA viroidal diversity.<sup>18</sup> This can also integrate the HERV RNA complementary DNA into the noncoding region of eukaryotic noncoding DNA using HERV integrase.<sup>19</sup> The noncoding DNA is lengthened by integrating HERV RNA complementary DNA with the integration going on as a continuing event. The archaea genome can also get integrated into human genome using integrase as has been described for trypanosomes.<sup>20</sup> The integrated archaea can undergo vertical transmission and can exist as genomic parasites.<sup>19, 20</sup> This increases the length and alters the grammar of the noncoding region producing memes or memory of acquired characters as well as eukaryotic speciation and individuality.<sup>21</sup> The HERV RNA complementary DNA can function as jumping genes producing a dynamic genome important in storage of synaptic information, HLA gene expression and developmental gene expression. The HERV RNA can regulate mRNA function by RNA interference.<sup>18</sup> The phenomena of RNA interference can modulate T-cell and B-cell function, insulin signalling lipid metabolism, cell growth and differentiation, apoptosis, neuronal transmission and euchromatin / heterochromatin expression.

The archaeal digoxin can regulate the nervous system including the NMDA / GABA thalamo-cortico-thalamic pathway mediating conscious perception.<sup>4, 22</sup> NMDA / GABA receptors can be modulated by digoxin induced calcium oscillations resulting NMDA / GAD activity induction.<sup>4</sup> The dipolar PAH and archaeal magnetite in the setting of digoxin induced sodium potassium ATPase inhibition can produce a pumped phonon system mediated Frohlich model superconducting state<sup>22</sup> inducing quantal perception with nanoarchaeal sensed gravity producing the orchestrated reduction of the quantal possibilities to the macroscopic world.<sup>4, 22</sup> The higher degree of integration of the archaea into the genome produces increased digoxin synthesis producing right hemispheric dominance and lesser degree producing left hemispheric dominance.<sup>4</sup> The

increased integration of archaea into the neuronal genome can produce increased digoxin mediated NMDA transmission producing schizophrenia and autism. Digoxin induced calcium oscillations can activate NF $\kappa$ B producing immune activation and cytokine secretion. The archaeal digoxin induced chronic immune activation can lead on to autoimmune disease.<sup>23</sup> Archaeal digoxin can induce the host AKT PI3K, AMPK, HIF alpha and NF $\kappa$ B producing the Warburg metabolic phenotype.<sup>24</sup> There is induction of glycolysis, inhibition of PDH activity and mitochondrial dysfunction resulting in inefficient energetics and metabolic syndrome. The archaeal digoxin generated cytokines can lead to TNF alpha induced insulin resistance and metabolic syndrome X. Digoxin induced sodium potassium ATPase inhibition can lead to increase in HMG CoA reductase activity and increased cholesterol synthesis. The increased cholesterol substrate also leads to increased archaeal growth and digoxin synthesis due to metabolic channeling to the mevalonate pathway. Digoxin can produce sodium-potassium ATPase inhibition and inward movement of plasma membrane cholesterol. This produces defective SREBP sensing, increased HMG CoA reductase activity and cholesterol synthesis. The digoxin induced inward movement of plasma membrane cholesterol can alter membrane cholesterol/sphingomyelin ratio producing modified lipid microdomains. The digoxin induced lipid microdomain modulation can regulate the GPCR couple adrenaline, noradrenaline, glucagon and neuropeptide receptors as well as protein tyrosine kinase linked insulin receptor. The digoxin mediated inhibition of nuclear membrane sodium-potassium ATPase can modulate nuclear membrane lipid microdomains and steroidal/thyroxine DNA receptor function. Thus endogenous digoxin can modulate all the endocrine receptors by regulating lipid microdomains. Hyperdigoxinemia is important in the pathogenesis of atherogenesis and metabolic syndrome X. Digoxin induced sodium-potassium ATPase inhibition results in an ATP sparing effect. Eighty

percent of the ATP generated is used to run the sodium-potassium ATPase pump. The digoxin inhibition of the sodium-potassium ATPase spares this ATP which is then used for lipid synthesis. Thus endogenous digoxin and the shadow biosphere generated Warburg phenotype can produce increased lipid synthesis and obesity important in metabolic syndrome X. Fat fuels insulin resistance by binding to the toll receptor and producing immune activation and immune infiltration of the adipose tissue. The archaeal digoxin induced monocyte activation and Warburg phenotype induced increased cholesterol synthesis leads to atherogenesis. The Warburg phenotype induced increased mitochondrial PT pore hexokinase can lead on to malignant transformation. The digoxin induced increased intracellular calcium can lead to PT pore dysfunction, cell death and neuronal degeneration.<sup>4</sup> The digoxin mediated transcribed HERV RNA can get encapsulated in microvesicles contributing to the retroviral state. The prion protein conformation is modulated by HERV RNA binding producing prion disease. The archaeal digoxin and rutile induced magnesium depletion can lead MPS deposition and produce EMF, CCP, MNG and mucoid angiopathy.<sup>4</sup> Thus the archaeal digoxin can produce neuro-immune-metabolic-endocrine-genetic integration. The increased archaeal cholesterol catabolism and digoxin secretion can lead to diverse pathological states of neuronal degeneration, metabolic syndrome X, autoimmune disease, malignancy and psychiatric disorders.

## References

- [1] Hanold D., Randies, J. W. (1991). Coconut cadang-cadang disease and its viroid agent, *Plant Disease*, 75, 330-335.
- [2] Valiathan M. S., Somers, K., Kartha, C. C. (1993). *Endomyocardial Fibrosis*. Delhi: Oxford University Press.
- [3] Edwin B. T., Mohankumaran, C. (2007). Kerala wilt disease phytoplasma: Phylogenetic analysis and identification of a vector, *Proutista moesta*, *Physiological and Molecular Plant Pathology*, 71 (1-3), 41-47.

- [4] Kurup R., Kurup, P. A. (2009). *Hypothalamic digoxin, cerebral dominance and brain function in health and diseases*. New York: Nova Science Publishers.
- [5] Eckburg P. B., Lepp, P. W., Relman, D. A. (2003). Archaea and their potential role in human disease, *Infect Immun*, 71, 591-596.
- [6] Smit A., Mushegian, A. (2000). Biosynthesis of isoprenoids via mevalonate in Archaea: the lost pathway, *Genome Res*, 10 (10), 1468-84.
- [7] Adam Z. (2007). Actinides and Life's Origins, *Astrobiology*, 7, 6-10.
- [8] Schoner W. (2002). Endogenous cardiac glycosides, a new class of steroid hormones, *Eur J Biochem*, 269, 2440-2448.
- [9] Davies P. C. W., Benner, S. A., Cleland, C. E., Lineweaver, C. H., McKay, C. P., Wolfe-Simon, F. (2009). Signatures of a Shadow Biosphere, *Astrobiology*, 10, 241-249.
- [10] Richmond W. (1973). Preparation and properties of a cholesterol oxidase from nocardia species and its application to the enzymatic assay of total cholesterol in serum, *Clin Chem*, 19, 1350-1356.
- [11] Snell E. D., Snell, C. T. (1961). *Colorimetric Methods of Analysis*. Vol 3A. New York: Van Nostrand.
- [12] Glick D. (1971). *Methods of Biochemical Analysis*. Vol 5. New York: Interscience Publishers.
- [13] Colowick, Kaplan, N. O. (1955). *Methods in Enzymology*. Vol 2. New York: Academic Press.
- [14] Van der Geize R., Yam, K., Heuser, T., Wilbrink, M. H., Hara, H., Anderton, M. C. (2007). A gene cluster encoding cholesterol catabolism in a soil actinomycete provides insight into Mycobacterium tuberculosis survival in macrophages, *Proc Natl Acad Sci USA*, 104 (6), 1947-52.
- [15] Francis A. J. (1998). Biotransformation of uranium and other actinides in radioactive wastes, *Journal of Alloys and Compounds*, 271 (273), 78-84.
- [16] Probian C., Wülfing, A., Harder, J. (2003). Anaerobic mineralization of quaternary carbon atoms: Isolation of denitrifying bacteria on pivalic acid (2,2-Dimethylpropionic acid), *Applied and Environmental Microbiology*, 69 (3), 1866-1870.

- [17] Vainshtein M., Suzina, N., Kudryashova, E., Ariskina, E. (2002). New Magnet-Sensitive Structures in Bacterial and Archaeal Cells, *Biol Cell*, 94 (1), 29-35.
- [18] Tsagris E. M., de Alba, A. E., Gozmanova, M., Kalantidis, K. (2008). Viroids, *Cell Microbiol*, 10, 2168.
- [19] Horie M., Honda, T., Suzuki, Y., Kobayashi, Y., Daito, T., Oshida, T. (2010). Endogenous non-retroviral RNA virus elements in mammalian genomes, *Nature*, 463, 84-87.
- [20] Hecht M., Nitz, N., Araujo, P., Sousa, A., Rosa, A., Gomes, D. (2010). Genes from Chagas parasite can transfer to humans and be passed on to children. Inheritance of DNA Transferred from American Trypanosomes to Human Hosts, *PLoS ONE*, 5, 2-10.
- [21] Flam F. (1994). Hints of a language in junk DNA, *Science*, 266, 1320.
- [22] Lockwood, M. (1989). *Mind, Brain and the Quantum*. Oxford: B. Blackwell.
- [23] Eberl M., Hintz, M., Reichenberg, A., Kollas, A., Wiesner, J., Jomaa, H. (2010). Microbial isoprenoid biosynthesis and human  $\gamma\delta$  T cell activation, *FEBS Letters*, 544 (1), 4-10.
- [24] Wallace D. C. (2005). Mitochondria and Cancer: Warburg Addressed, *Cold Spring Harbor Symposia on Quantitative Biology*, 70, 363-374.

